Pfizer's failed pregabalin patent appeal means NHS could reclaim £502m The NHS could claim back over half a billion pounds from Pfizer - following a long-running controversy that saw GPs having to switch patients between generic and branded pregabalin - after the Supreme Court ruled that the drug company’s patent for Lyrica (pregabalin) is invalid.
The judgement, handed down this morning, dismissed Pfizer’s final attempt to uphold its patent, and accused the company of trying to hold a ‘monopoly’ with ‘insufficient’ evidence. Pulse
No comments:
Post a Comment